Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 1
1952 1
1957 1
1959 1
1960 1
1962 1
1963 1
1964 2
1966 7
1967 8
1968 7
1969 5
1970 5
1971 5
1972 2
1973 6
1975 9
1976 3
1977 2
1978 2
1979 2
1980 5
1981 8
1982 4
1983 15
1984 11
1985 4
1986 6
1987 6
1988 20
1989 20
1990 19
1991 15
1992 16
1993 17
1994 18
1995 27
1996 40
1997 41
1998 39
1999 60
2000 60
2001 103
2002 97
2003 134
2004 152
2005 196
2006 243
2007 291
2008 366
2009 347
2010 469
2011 538
2012 623
2013 660
2014 719
2015 754
2016 714
2017 815
2018 861
2019 978
2020 1097
2021 1171
2022 999
2023 984
2024 1062
2025 1214
2026 823

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,942 results

Results by year

Filters applied: . Clear all
Page 1
Idiopathic inflammatory myopathies: a review.
Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Ashton C, et al. Intern Med J. 2021 Jun;51(6):845-852. doi: 10.1111/imj.15358. Intern Med J. 2021. PMID: 34155760 Review.
Idiopathic inflammatory myopathy (IIM) is the umbrella term including dermatomyositis (DM), polymyositis (PM), overlap myositis (OM), sporadic inclusion body myositis (IBM) and necrotising autoimmune myopathy (NAM), also known as immune-mediated necrotising myopathy. There …
Idiopathic inflammatory myopathy (IIM) is the umbrella term including dermatomyositis (DM), polymyositis (PM), overlap myositis (OM), sporad …
FDA/CDER/OND Experience With New Approach Methodologies (NAMs).
Yao J, Peretz J, Bebenek I, Avila A, Alapatt T, Lee B, Patel D, Brown P, Davis-Bruno K. Yao J, et al. Int J Toxicol. 2026 Mar-Apr;45(2):136-156. doi: 10.1177/10915818251384270. Epub 2025 Nov 13. Int J Toxicol. 2026. PMID: 41231273 Free PMC article.
Furthermore, we provide a CDER/OND Pharmacology/Toxicology reviewer perspective on the future of NAM incorporation into nonclinical development programs for new drugs as scientific technology continues to evolve. Ultimately, we hope that by sharing the FDA/CDER/OND experie …
Furthermore, we provide a CDER/OND Pharmacology/Toxicology reviewer perspective on the future of NAM incorporation into nonclinical d …
NAM Therapy-Evidence-Based Results.
Esenlik E, Gibson T, Kassam S, Sato Y, Garfinkle J, Figueroa AA, AlQatami F, Runyan C, Alperovich M, Golinko MS, Lee C, Chatzigianni A, Zafeiriadis AA, Santiago P, Hosseinian B, Kaygısız EU, Üçüncü N, Aslan BI, Uzuner FD, Gülşen A, Akkurt A, Arslan SG, Sabás M, Muñoz-Mendoza MA, Masis D, Holguin L, Granados A, Rojas NE, Campo B, Keskin K, Akçam MO, Lowe KM, Morselli PG, Pannuto L, Yarza IN, Martinez AT, Coşkun EY, Nissan S. Esenlik E, et al. Cleft Palate Craniofac J. 2020 Apr;57(4):529-531. doi: 10.1177/1055665619899752. Epub 2020 Jan 21. Cleft Palate Craniofac J. 2020. PMID: 31960709 Review.
As with any treatment methodology, nasoalveolar molding (NAM) has both benefits and limitations. Commonly cited concerns with NAM, and PSIO in general, include increased cost, increased burden of care, and a negative impact on maxillary growth. ...A review of the li …
As with any treatment methodology, nasoalveolar molding (NAM) has both benefits and limitations. Commonly cited concerns with NAM …
Nicotinamide and pyridoxine stimulate muscle stem cell expansion and enhance regenerative capacity during aging.
Ancel S, Michaud J, Migliavacca E, Jomard C, Fessard A, Garcia P, Karaz S, Raja S, Jacot GE, Desgeorges T, Sánchez-García JL, Tauzin L, Ratinaud Y, Brinon B, Métairon S, Pinero L, Barron D, Blum S, Karagounis LG, Heshmat R, Ostovar A, Farzadfar F, Scionti I, Mounier R, Gondin J, Stuelsatz P, Feige JN. Ancel S, et al. J Clin Invest. 2024 Nov 12;134(24):e163648. doi: 10.1172/JCI163648. J Clin Invest. 2024. PMID: 39531334 Free PMC article.
NAM and PN synergize via CK1-mediated cytoplasmic beta-catenin activation and AKT signaling to promote amplification and differentiation of MuSCs. ...Levels of NAM and bioactive PN spontaneously declined during aging in model organisms and interindependently associa …
NAM and PN synergize via CK1-mediated cytoplasmic beta-catenin activation and AKT signaling to promote amplification and differentiat …
Nicotinamide and acute kidney injury.
Fontecha-Barriuso M, Lopez-Diaz AM, Carriazo S, Ortiz A, Sanz AB. Fontecha-Barriuso M, et al. Clin Kidney J. 2021 Sep 23;14(12):2453-2462. doi: 10.1093/ckj/sfab173. eCollection 2021 Dec. Clin Kidney J. 2021. PMID: 34950458 Free PMC article.
In a recent issue of ckj, Piedrafita et al. reported that urine tryptophan and kynurenine are reduced in cardiac bypass surgery patients that develop acute kidney injury (AKI), suggesting reduced activity of the kynurenine pathway of nicotinamide (NAM) adenine dinucleotide …
In a recent issue of ckj, Piedrafita et al. reported that urine tryptophan and kynurenine are reduced in cardiac bypass surgery patients tha …
Overcoming Increasing Morbid Obesity in Korea.
Huh Y, Nam GE. Huh Y, et al. J Obes Metab Syndr. 2021 Jun 30;30(2):77-80. doi: 10.7570/jomes21052. J Obes Metab Syndr. 2021. PMID: 34187966 Free PMC article. No abstract available.
READER'S FORUM.
Nam SH. Nam SH. Korean J Orthod. 2025 Jan 25;55(1):1-2. doi: 10.4041/kjod55.0001RF. Korean J Orthod. 2025. PMID: 39849961 Free PMC article. No abstract available.
The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans.
Christen S, Redeuil K, Goulet L, Giner MP, Breton I, Rota R, Frézal A, Nazari A, Van den Abbeele P, Godin JP, Nutten S, Cuenoud B. Christen S, et al. Nat Metab. 2026 Jan;8(1):62-73. doi: 10.1038/s42255-025-01421-8. Epub 2026 Jan 15. Nat Metab. 2026. PMID: 41540253 Free PMC article. Clinical Trial.
Here we show in a randomized, open-label, placebo-controlled study in 65 healthy participants that 14 days of supplementation with NR and NMN, but not Nam, comparably increases circulatory NAD(+) concentrations in healthy adults. Unlike the chronic effect, only Nam …
Here we show in a randomized, open-label, placebo-controlled study in 65 healthy participants that 14 days of supplementation with NR and NM …
14,942 results
You have reached the last available page of results. Please see the User Guide for more information.